-Company ramps up clinical diagnostics product development- NEW HAVEN, Conn., July 17
NEW HAVEN, Conn., July 17 /PRNewswire/ -- HistoRx, Inc., announced today
that William C. Sullivan has joined the company as Senior Vice President,
Diagnostic Operations. In this newly created position, Mr. Sullivan will be
responsible for expanding the role of the company's diagnostics development
process, overseeing the manufacture of HistoRx diagnostic products, and
growing revenues associated with the clinical diagnostics services provided by
HistoRx.
"I am delighted to have this opportunity to join HistoRx at such a
promising time for the company," said Mr. Sullivan. "HistoRx has made
impressive progress over the past several years in building a company that is
well-poised with its unique AQUA(R) technology platform to capitalize on the
tremendous opportunity that personalized medicine represents, powered by an
expanding revenue-generating services operation. I look forward to leading the
commercial laboratory operations for HistoRx's growing number of
pharmaceutical and biotechnology customers as we focus concurrently on
developing and commercializing our own line of HistoRx high-value clinical
diagnostic products."
"The HistoRx management team, operations workforce, and Board of Directors
are very pleased to have Bill join the company," said Rana Gupta, CEO of
HistoRx. "Over the past year, we have moved the company rapidly toward our
ultimate goal of introducing HistoRx-branded, FDA-approved, quantitative
diagnostic tests that run on the proprietary HistoRx AQUA(R) technology. We
believe these assays will offer significant improvements over currently
available immunohistochemistry-based tests and drive standards-based market
adoption of our technology. With his impressive diagnostics industry expertise
combined with operations management experience, Bill will be a tremendous
asset to HistoRx in leading our commercial laboratory operations and
diagnostic product development."
Mr. Sullivan brings to HistoRx an accomplished management record, with
more than 25 years of experience leading operations of technology-driven
businesses in the in vitro diagnostics and medical devices industries. He was
previously Vice President, Corporate Operations of Vermillion, Inc. (formerly
Ciphergen Biosystems, Inc.); prior to that, he served as Vice President,
Diagnostic Manufacturing at Visible Genetics and as Vice President, Operations
at the Nichols Institute Diagnostics (a subsidiary of Quest Diagnostics),
among positions with other diagnostics and medical device companies. Mr.
Sullivan also served as a consultant to diagnostics and medical device
companies, specializing in manufacturing operations for FDA-regulated
facilities and products. He earned a B.A. from The College of the Holy Cross
in Worcester, Massachusetts and pursued graduate studies in the Department of
Pathology at the University of Pennsylvania.
About HistoRx ( www.historx.com )
HistoRx, Inc. is a leader in the emerging field of tissue-based diagnostic
products for targeted patient treatment. HistoRx is developing and
commercializing novel diagnostic products and services based on the company's
pioneering AQUA(R) tissue biomarker analysis technology, which provides
exceptional measurement and localization of protein biomarkers in their
natural context within tissue. The proprietary AQUA(R) technology is the first
platform capable of measuring biomarker concentration with subcellular
resolution to generate more precise, efficient, and cost-effective answers
about the safety and effectiveness of new therapeutics in development as well
as enable the development of companion diagnostic tests for targeted
therapies. HistoRx services are used by pharmaceutical and biotechnology
companies throughout discovery research, preclinical studies, and clinical
drug development. HistoRx also develops companion diagnostic products that are
linked to partners' drug candidates in development to predict therapeutic
outcome, which HistoRx will co-market with its partners' targeted
therapeutics. These partnerships provide the basis for HistoRx to pursue
internal programs to develop proprietary in vitro diagnostics that offer
substantial improvements in treatment decision-making and patient outcomes
compared with existing immunohistochemistry-based tests.
CONTACT:
Mary Moynihan
M2Friend Biocommunications
(802)951-9600
mary@m2friend.com
SOURCE HistoRx, Inc.
